MaxCyte, trading on the London Stock Exchange under MXCT.L, reported QQ1 2025 revenue of $10.39 million, down 8.4% year over year but up 19.5% quarter over quarter versus Q4 2024. The company delivered a strong gross margin of 85.6%, with gross profit of $8.89 million, signaling favorable product mix and high contribution from current product lines. However, operating losses persisted as research and development and selling/general administrative expenses remained elevated, resulting in an EBITDA of -$10.17 million and a net income of -$10.26 million for the quarter. Earnings per share stood at -$0.10.
From a liquidity perspective, MaxCyte ended QQ1 2025 with cash and cash equivalents of approximately $23.39 million and a net cash position of about -$4.56 million (net debt negative due to cash exceeding gross debt). Free cash flow for the quarter was -$15.06 million, driven by operating cash flow of -$14.41 million and modest capital expenditures of $0.65 million. The balance sheet remains asset-light in terms of liquidity risk given very strong current ratios (current ratio 12.23, quick ratio 11.58, cash ratio 1.84) but is burdened by a large accumulated deficit (retained earnings of -$227.11 million).
Strategically, the company is accelerating investments in its ExPERT platform family (ATx/ STx/ GTx/ VLx) and PAs to support broader cell therapy workflows, including large-scale transfection applications. The near-term profitability path remains contingent on revenue growth and continued cost discipline; absent a material uplift in quarterly revenue and/or a meaningful reduction in operating expenses as a percentage of revenue, the company is unlikely to reach EBITDA breakeven in the near term. The market valuation remains elevated relative to revenue due to growth expectations, as reflected in a price-to-sales multiple around 27.8x, underscoring the premium placed on long-term platform adoption and pipeline success.